INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.
The purpose of the study is to see how well patients with relapsed or refractory lymphoma
respond to treatment with Gemcitabine and Irinotecan. Patients on this study take part
because they have relapsed or refractory lymphoma. Additionally, the study will assess
treatment-related side effects and time until disease progression or recurrence.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Assess the response rate in patients with recurrent or refractory B-cell NHL or Hodgkins disease, treated with the combination of the gemcitabine and irinotecan.
Ian Rabinowitz, MD
University of New Mexico
United States: Institutional Review Board
|University of New Mexico||Albuquerque, New Mexico 87131|
|Lovelace Sandia Health Systems Dept of Hematology||Albuquerque, New Mexico 87108|